Adjunctive Azithromycin Prophylaxis for Prelabor Cesarean Birth

To evaluate maternal postoperative infections before and after addition of adjunctive azithromycin to standard antibiotic prophylaxis for prelabor cesarean births. We conducted a retrospective cohort study of patients with singleton gestations at more than 23 weeks of gestation who underwent prelabo...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Obstetrics and gynecology (New York. 1953) 2023-02, Vol.141 (2), p.403-413
Hauptverfasser: Ruzic, Martha F., Blanchard, Christina T., Cozzi, Gabriella D., Howard, Hannah R., Casey, Brian M., Tita, Alan T., Kim, Dhong-Jin, Szychowski, Jeff M., Subramaniam, Akila
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 413
container_issue 2
container_start_page 403
container_title Obstetrics and gynecology (New York. 1953)
container_volume 141
creator Ruzic, Martha F.
Blanchard, Christina T.
Cozzi, Gabriella D.
Howard, Hannah R.
Casey, Brian M.
Tita, Alan T.
Kim, Dhong-Jin
Szychowski, Jeff M.
Subramaniam, Akila
description To evaluate maternal postoperative infections before and after addition of adjunctive azithromycin to standard antibiotic prophylaxis for prelabor cesarean births. We conducted a retrospective cohort study of patients with singleton gestations at more than 23 weeks of gestation who underwent prelabor cesarean birth at a single tertiary care center. Deliveries were categorized as those before implementation of 500 mg intravenous azithromycin in addition to standard preoperative cephalosporin antibiotic prophylaxis (pre-AZI group; January 2013-September 2015) and those after implementation of adjunctive azithromycin (post-AZI group; January 2016-December 2018). Cesarean births from October to December 2015 were excluded as a washout period. The primary outcome was a composite of postcesarean infections (endometritis, superficial or deep wound infections, intra-abdominal abscess, urinary tract infections). Secondary outcomes included composite components, other wound or postoperative complications, and select neonatal morbidities. Outcomes were compared between groups, and adjusted odds ratios (aORs) and 95% CIs were calculated using multivariable analysis. Propensity score matching was performed to assess the robustness our analysis. Of 2,867 delivering patients included for analysis, 1,391 (48.5%) were in the pre-AZI group and 1,476 (51.5%) were in the post-AZI group. Patients in the post-AZI group were older and were more likely to have private insurance, use aspirin, and receive predelivery antibiotics within 2 weeks. There were significantly lower odds of composite infection after azithromycin implementation (3.3% vs 4.8%, aOR 0.60, 95% CI 0.40-0.89), driven by a reduction in wound infection odds (2.4% vs 3.5%, aOR 0.61, 95% CI 0.39-0.98). There were lower odds of other postpartum complications, including wound seroma (0.5% vs 0.9%, aOR 0.34, 95% CI 0.13-0.90) and dehiscence (0.5% vs 1.2%, aOR 0.32, 95% CI 0.13-0.79). There were no differences in select neonatal morbidities between groups. Of 1,138 matching sets in the propensity analysis, the primary outcome remained significantly lower in the post-AZI group (aOR 0.64, 95% CI 0.41-0.99). Adopting adjunctive azithromycin for prelabor cesarean deliveries was associated with lower odds of postpartum infection.
doi_str_mv 10.1097/AOG.0000000000005037
format Article
fullrecord <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1097_AOG_0000000000005037</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>36649335</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3030-266c8f6f39d82032db5891c4208752475e4ef9f2d3dda018a7218ef5a3d8cf6b3</originalsourceid><addsrcrecordid>eNpdkNtKw0AQhhdRbK2-gUheIHV3J3vIlcSiVRDqhYJ3YbMHkpo2ZTe11qd3tZ5wYJgZmP9n5kPolOAxwbk4L2bTMf4TDIPYQ0MiBaQU4GkfDTGmeSpklg3QUQjzuER4DodoAJxnOQAboovCzNdL3TcvNinemr723WKrm2Vy77tVvW3VaxMS1_k421ZVsZnYoLxVy-Sy8X19jA6caoM9-aoj9Hh99TC5Se9m09tJcZdqwIBTyrmWjjvIjaQYqKmYzInOKJaC0Uwwm1mXO2rAGIWJVIISaR1TYKR2vIIRyna-2ncheOvKlW8Wym9LgssPHmXkUf7nEWVnO9lqXS2s-RF9A_j13XRtb314btcb68vaqravP_04ZfF-TAHTOKUx4wPvVdJqZg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Adjunctive Azithromycin Prophylaxis for Prelabor Cesarean Birth</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>Ruzic, Martha F. ; Blanchard, Christina T. ; Cozzi, Gabriella D. ; Howard, Hannah R. ; Casey, Brian M. ; Tita, Alan T. ; Kim, Dhong-Jin ; Szychowski, Jeff M. ; Subramaniam, Akila</creator><creatorcontrib>Ruzic, Martha F. ; Blanchard, Christina T. ; Cozzi, Gabriella D. ; Howard, Hannah R. ; Casey, Brian M. ; Tita, Alan T. ; Kim, Dhong-Jin ; Szychowski, Jeff M. ; Subramaniam, Akila</creatorcontrib><description>To evaluate maternal postoperative infections before and after addition of adjunctive azithromycin to standard antibiotic prophylaxis for prelabor cesarean births. We conducted a retrospective cohort study of patients with singleton gestations at more than 23 weeks of gestation who underwent prelabor cesarean birth at a single tertiary care center. Deliveries were categorized as those before implementation of 500 mg intravenous azithromycin in addition to standard preoperative cephalosporin antibiotic prophylaxis (pre-AZI group; January 2013-September 2015) and those after implementation of adjunctive azithromycin (post-AZI group; January 2016-December 2018). Cesarean births from October to December 2015 were excluded as a washout period. The primary outcome was a composite of postcesarean infections (endometritis, superficial or deep wound infections, intra-abdominal abscess, urinary tract infections). Secondary outcomes included composite components, other wound or postoperative complications, and select neonatal morbidities. Outcomes were compared between groups, and adjusted odds ratios (aORs) and 95% CIs were calculated using multivariable analysis. Propensity score matching was performed to assess the robustness our analysis. Of 2,867 delivering patients included for analysis, 1,391 (48.5%) were in the pre-AZI group and 1,476 (51.5%) were in the post-AZI group. Patients in the post-AZI group were older and were more likely to have private insurance, use aspirin, and receive predelivery antibiotics within 2 weeks. There were significantly lower odds of composite infection after azithromycin implementation (3.3% vs 4.8%, aOR 0.60, 95% CI 0.40-0.89), driven by a reduction in wound infection odds (2.4% vs 3.5%, aOR 0.61, 95% CI 0.39-0.98). There were lower odds of other postpartum complications, including wound seroma (0.5% vs 0.9%, aOR 0.34, 95% CI 0.13-0.90) and dehiscence (0.5% vs 1.2%, aOR 0.32, 95% CI 0.13-0.79). There were no differences in select neonatal morbidities between groups. Of 1,138 matching sets in the propensity analysis, the primary outcome remained significantly lower in the post-AZI group (aOR 0.64, 95% CI 0.41-0.99). Adopting adjunctive azithromycin for prelabor cesarean deliveries was associated with lower odds of postpartum infection.</description><identifier>ISSN: 0029-7844</identifier><identifier>EISSN: 1873-233X</identifier><identifier>DOI: 10.1097/AOG.0000000000005037</identifier><identifier>PMID: 36649335</identifier><language>eng</language><publisher>United States: Lippincott Williams &amp; Wilkins</publisher><subject>Anti-Bacterial Agents - therapeutic use ; Antibiotic Prophylaxis - adverse effects ; Azithromycin - therapeutic use ; Cesarean Section - adverse effects ; Female ; Humans ; Infant, Newborn ; Postoperative Complications - prevention &amp; control ; Pregnancy ; Retrospective Studies ; Surgical Wound Infection - epidemiology ; Surgical Wound Infection - prevention &amp; control</subject><ispartof>Obstetrics and gynecology (New York. 1953), 2023-02, Vol.141 (2), p.403-413</ispartof><rights>Lippincott Williams &amp; Wilkins</rights><rights>Copyright © 2023 by the American College of Obstetricians and Gynecologists. Published by Wolters Kluwer Health, Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3030-266c8f6f39d82032db5891c4208752475e4ef9f2d3dda018a7218ef5a3d8cf6b3</citedby><cites>FETCH-LOGICAL-c3030-266c8f6f39d82032db5891c4208752475e4ef9f2d3dda018a7218ef5a3d8cf6b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36649335$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ruzic, Martha F.</creatorcontrib><creatorcontrib>Blanchard, Christina T.</creatorcontrib><creatorcontrib>Cozzi, Gabriella D.</creatorcontrib><creatorcontrib>Howard, Hannah R.</creatorcontrib><creatorcontrib>Casey, Brian M.</creatorcontrib><creatorcontrib>Tita, Alan T.</creatorcontrib><creatorcontrib>Kim, Dhong-Jin</creatorcontrib><creatorcontrib>Szychowski, Jeff M.</creatorcontrib><creatorcontrib>Subramaniam, Akila</creatorcontrib><title>Adjunctive Azithromycin Prophylaxis for Prelabor Cesarean Birth</title><title>Obstetrics and gynecology (New York. 1953)</title><addtitle>Obstet Gynecol</addtitle><description>To evaluate maternal postoperative infections before and after addition of adjunctive azithromycin to standard antibiotic prophylaxis for prelabor cesarean births. We conducted a retrospective cohort study of patients with singleton gestations at more than 23 weeks of gestation who underwent prelabor cesarean birth at a single tertiary care center. Deliveries were categorized as those before implementation of 500 mg intravenous azithromycin in addition to standard preoperative cephalosporin antibiotic prophylaxis (pre-AZI group; January 2013-September 2015) and those after implementation of adjunctive azithromycin (post-AZI group; January 2016-December 2018). Cesarean births from October to December 2015 were excluded as a washout period. The primary outcome was a composite of postcesarean infections (endometritis, superficial or deep wound infections, intra-abdominal abscess, urinary tract infections). Secondary outcomes included composite components, other wound or postoperative complications, and select neonatal morbidities. Outcomes were compared between groups, and adjusted odds ratios (aORs) and 95% CIs were calculated using multivariable analysis. Propensity score matching was performed to assess the robustness our analysis. Of 2,867 delivering patients included for analysis, 1,391 (48.5%) were in the pre-AZI group and 1,476 (51.5%) were in the post-AZI group. Patients in the post-AZI group were older and were more likely to have private insurance, use aspirin, and receive predelivery antibiotics within 2 weeks. There were significantly lower odds of composite infection after azithromycin implementation (3.3% vs 4.8%, aOR 0.60, 95% CI 0.40-0.89), driven by a reduction in wound infection odds (2.4% vs 3.5%, aOR 0.61, 95% CI 0.39-0.98). There were lower odds of other postpartum complications, including wound seroma (0.5% vs 0.9%, aOR 0.34, 95% CI 0.13-0.90) and dehiscence (0.5% vs 1.2%, aOR 0.32, 95% CI 0.13-0.79). There were no differences in select neonatal morbidities between groups. Of 1,138 matching sets in the propensity analysis, the primary outcome remained significantly lower in the post-AZI group (aOR 0.64, 95% CI 0.41-0.99). Adopting adjunctive azithromycin for prelabor cesarean deliveries was associated with lower odds of postpartum infection.</description><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Antibiotic Prophylaxis - adverse effects</subject><subject>Azithromycin - therapeutic use</subject><subject>Cesarean Section - adverse effects</subject><subject>Female</subject><subject>Humans</subject><subject>Infant, Newborn</subject><subject>Postoperative Complications - prevention &amp; control</subject><subject>Pregnancy</subject><subject>Retrospective Studies</subject><subject>Surgical Wound Infection - epidemiology</subject><subject>Surgical Wound Infection - prevention &amp; control</subject><issn>0029-7844</issn><issn>1873-233X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkNtKw0AQhhdRbK2-gUheIHV3J3vIlcSiVRDqhYJ3YbMHkpo2ZTe11qd3tZ5wYJgZmP9n5kPolOAxwbk4L2bTMf4TDIPYQ0MiBaQU4GkfDTGmeSpklg3QUQjzuER4DodoAJxnOQAboovCzNdL3TcvNinemr723WKrm2Vy77tVvW3VaxMS1_k421ZVsZnYoLxVy-Sy8X19jA6caoM9-aoj9Hh99TC5Se9m09tJcZdqwIBTyrmWjjvIjaQYqKmYzInOKJaC0Uwwm1mXO2rAGIWJVIISaR1TYKR2vIIRyna-2ncheOvKlW8Wym9LgssPHmXkUf7nEWVnO9lqXS2s-RF9A_j13XRtb314btcb68vaqravP_04ZfF-TAHTOKUx4wPvVdJqZg</recordid><startdate>20230201</startdate><enddate>20230201</enddate><creator>Ruzic, Martha F.</creator><creator>Blanchard, Christina T.</creator><creator>Cozzi, Gabriella D.</creator><creator>Howard, Hannah R.</creator><creator>Casey, Brian M.</creator><creator>Tita, Alan T.</creator><creator>Kim, Dhong-Jin</creator><creator>Szychowski, Jeff M.</creator><creator>Subramaniam, Akila</creator><general>Lippincott Williams &amp; Wilkins</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20230201</creationdate><title>Adjunctive Azithromycin Prophylaxis for Prelabor Cesarean Birth</title><author>Ruzic, Martha F. ; Blanchard, Christina T. ; Cozzi, Gabriella D. ; Howard, Hannah R. ; Casey, Brian M. ; Tita, Alan T. ; Kim, Dhong-Jin ; Szychowski, Jeff M. ; Subramaniam, Akila</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3030-266c8f6f39d82032db5891c4208752475e4ef9f2d3dda018a7218ef5a3d8cf6b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Antibiotic Prophylaxis - adverse effects</topic><topic>Azithromycin - therapeutic use</topic><topic>Cesarean Section - adverse effects</topic><topic>Female</topic><topic>Humans</topic><topic>Infant, Newborn</topic><topic>Postoperative Complications - prevention &amp; control</topic><topic>Pregnancy</topic><topic>Retrospective Studies</topic><topic>Surgical Wound Infection - epidemiology</topic><topic>Surgical Wound Infection - prevention &amp; control</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ruzic, Martha F.</creatorcontrib><creatorcontrib>Blanchard, Christina T.</creatorcontrib><creatorcontrib>Cozzi, Gabriella D.</creatorcontrib><creatorcontrib>Howard, Hannah R.</creatorcontrib><creatorcontrib>Casey, Brian M.</creatorcontrib><creatorcontrib>Tita, Alan T.</creatorcontrib><creatorcontrib>Kim, Dhong-Jin</creatorcontrib><creatorcontrib>Szychowski, Jeff M.</creatorcontrib><creatorcontrib>Subramaniam, Akila</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Obstetrics and gynecology (New York. 1953)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ruzic, Martha F.</au><au>Blanchard, Christina T.</au><au>Cozzi, Gabriella D.</au><au>Howard, Hannah R.</au><au>Casey, Brian M.</au><au>Tita, Alan T.</au><au>Kim, Dhong-Jin</au><au>Szychowski, Jeff M.</au><au>Subramaniam, Akila</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Adjunctive Azithromycin Prophylaxis for Prelabor Cesarean Birth</atitle><jtitle>Obstetrics and gynecology (New York. 1953)</jtitle><addtitle>Obstet Gynecol</addtitle><date>2023-02-01</date><risdate>2023</risdate><volume>141</volume><issue>2</issue><spage>403</spage><epage>413</epage><pages>403-413</pages><issn>0029-7844</issn><eissn>1873-233X</eissn><abstract>To evaluate maternal postoperative infections before and after addition of adjunctive azithromycin to standard antibiotic prophylaxis for prelabor cesarean births. We conducted a retrospective cohort study of patients with singleton gestations at more than 23 weeks of gestation who underwent prelabor cesarean birth at a single tertiary care center. Deliveries were categorized as those before implementation of 500 mg intravenous azithromycin in addition to standard preoperative cephalosporin antibiotic prophylaxis (pre-AZI group; January 2013-September 2015) and those after implementation of adjunctive azithromycin (post-AZI group; January 2016-December 2018). Cesarean births from October to December 2015 were excluded as a washout period. The primary outcome was a composite of postcesarean infections (endometritis, superficial or deep wound infections, intra-abdominal abscess, urinary tract infections). Secondary outcomes included composite components, other wound or postoperative complications, and select neonatal morbidities. Outcomes were compared between groups, and adjusted odds ratios (aORs) and 95% CIs were calculated using multivariable analysis. Propensity score matching was performed to assess the robustness our analysis. Of 2,867 delivering patients included for analysis, 1,391 (48.5%) were in the pre-AZI group and 1,476 (51.5%) were in the post-AZI group. Patients in the post-AZI group were older and were more likely to have private insurance, use aspirin, and receive predelivery antibiotics within 2 weeks. There were significantly lower odds of composite infection after azithromycin implementation (3.3% vs 4.8%, aOR 0.60, 95% CI 0.40-0.89), driven by a reduction in wound infection odds (2.4% vs 3.5%, aOR 0.61, 95% CI 0.39-0.98). There were lower odds of other postpartum complications, including wound seroma (0.5% vs 0.9%, aOR 0.34, 95% CI 0.13-0.90) and dehiscence (0.5% vs 1.2%, aOR 0.32, 95% CI 0.13-0.79). There were no differences in select neonatal morbidities between groups. Of 1,138 matching sets in the propensity analysis, the primary outcome remained significantly lower in the post-AZI group (aOR 0.64, 95% CI 0.41-0.99). Adopting adjunctive azithromycin for prelabor cesarean deliveries was associated with lower odds of postpartum infection.</abstract><cop>United States</cop><pub>Lippincott Williams &amp; Wilkins</pub><pmid>36649335</pmid><doi>10.1097/AOG.0000000000005037</doi><tpages>11</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0029-7844
ispartof Obstetrics and gynecology (New York. 1953), 2023-02, Vol.141 (2), p.403-413
issn 0029-7844
1873-233X
language eng
recordid cdi_crossref_primary_10_1097_AOG_0000000000005037
source MEDLINE; Journals@Ovid Complete
subjects Anti-Bacterial Agents - therapeutic use
Antibiotic Prophylaxis - adverse effects
Azithromycin - therapeutic use
Cesarean Section - adverse effects
Female
Humans
Infant, Newborn
Postoperative Complications - prevention & control
Pregnancy
Retrospective Studies
Surgical Wound Infection - epidemiology
Surgical Wound Infection - prevention & control
title Adjunctive Azithromycin Prophylaxis for Prelabor Cesarean Birth
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T20%3A41%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Adjunctive%20Azithromycin%20Prophylaxis%20for%20Prelabor%20Cesarean%20Birth&rft.jtitle=Obstetrics%20and%20gynecology%20(New%20York.%201953)&rft.au=Ruzic,%20Martha%20F.&rft.date=2023-02-01&rft.volume=141&rft.issue=2&rft.spage=403&rft.epage=413&rft.pages=403-413&rft.issn=0029-7844&rft.eissn=1873-233X&rft_id=info:doi/10.1097/AOG.0000000000005037&rft_dat=%3Cpubmed_cross%3E36649335%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/36649335&rfr_iscdi=true